Latest filing published 13 Jun 2025 for Haemonetics CORP. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Michelle L. Basil (senior executive) discloses dealings in Haemonetics Corp to SEC (Form 4). The record holds 22 filings, for trades running from 17 May 2021 to 30 May 2025.
Sales make up the whole of the open-market record (9 sales, €364k). Other entries cover 11 share grants and 2 option exercises.
The record was last updated on 13 June 2025 with a share grant in Haemonetics Corp. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
22 of 22 declarations